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72 Poster Session-Itransplant for graft failure). Average pre apheresis costs per patient
were $1800 (clinic visit, laboratory evaluation, central venous cathe-
ter insertion, and chest x-ray to check placement). The average costs
of chemotherapy administration, hospitalization, prophylactic anti-
biotics and G-CSF were $29181 (not including rituximab). This
does not include supportive care, I/V fluids, readmission costs or
professional fees. Post apheresis costs were $2493.
Conclusions: Interventions or newer agents that reduce the fail-
ure rate or the number of apheresis procedures required to reach
a target HPC dose without increasing the toxicity may reduce total
transplant costs.The financial implication for transplant centers
where reimbursement is DRG (diagnosis related group) or case
rate based is significant.
Estimated Chemo Mobilization Costs
National Hospital Median Estimated Total
Cost Item Average Cost (USD) (Range) Costs (USD)Daily room charge
for chemo
administration$863 6 (3–28) $5,178Ifosfamide 3.33 g/m2/d
x 3 d$372.87/gram 19.38g $7,227Etoposide 150mg/m2
 6 d$17.61/10mg 1,746mg $3,074Daily CBC, diff $93 5 (3–28) $465
Readmission, daily
room charge
(n524)$863 5 (1–12) $4,315Blood transfusions
(n564)$494 1.4 (0–6) $692Platelet transfusions
(n564)$494 1.5 (0–7) $741Oral antibiotics 9 (0–16) $104
Apheresis procedure $1,917.73 2 (1–7) $3,835
PB CD341 analysis $135 2 (estimated) $270
Total (without rituximab) $36,454Source: Cleverly and Associates; www.drugstore.com; Redbooke;
Thompson PDR.195
SALVAGE AND HEMATOPOIETIC RECOVERY WITH BORTEZOMIB AND
MELPHALAN IN CYTOPENIC RECURRENT AND REFRACTORY MULTIPLE
MYELOMA
Mazumder, A., Vesole, D., Jagannath, S. St. Vincents Cancer Center,
New York, NY
The management of relapsed and refractory multiple myeloma
(RRMM) remains difficult. Patients have short response duration,
become cytopenic and are not eligible for clinical trials of promising
new drugs. They often have inadequate numbers of stem cells (\3
10(6) CD34/kg) remaining for amyeloablative transplant. Thus, new
approaches are needed.We therefore initiated a pilot clinical trial to
enable the successful reconstitution of blood counts in patients with
RRMM so they could proceed onto new clinical trials and test the
synergy of bortezomib and melphalan clinically in non-myeloabla-
tive doses (stem cell boost). We have treated 9 patients with
RRMM who have failed novel agents (including bortezomib) and
chemotherapy (dexamethasone, cytoxan, etoposide, cisplatin, and
doxil) and who had only limited duration of response previously
with high dose melphalan. All patients were cytopenic (ANC \
1000 and/or platelets\ 50,000/ mcl) and thus not eligible for new
clinical trials. The melphalan was given at 30–50 mg/m2 on days 1
and 4, depending on the age and performance status of the patient.
Bortezomib at 1.3 mg/m2 was given on the same days after the mel-
phalan. The patients then received 1.5 to 2.2 10(6) CD34 cells/kg.
(depending upon the amount of remaining stem cells). We have seen
responses (.25%) in all 9, with.PR in 8 and VGPR in 1. More im-
portantly, all patients successfully engraftedWBC.2000 and plate-
lets.50,000/mcl. Duration of response was 2 months or greater and
all patients were able to proceed on to new clinical trials. All patients
were given treatment as outpatient and average duration of hospital-ization was 3 days (range 0 to 6) during cytopenia. Thus, the clinical
synergy between bortezomib and melphalan can lead to an effective
salvage strategy even for cytopenic patients with relapsed and refrac-
tory multiple myeloma. This non-myeloablative approach could
serve as a platform for proceeding on to new clinical trials for those
advanced patients without adequate numbers of stem cells for a -
myeloablative transplant.PEDIATRIC DISORDERS
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OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN PEDIATRIC PATIENTSWITH PRIMARY AND SECONDARYMYELO-
DYSPLASTIC SYNDROMES
Parikh, S.H.1, Mendizabal, A.2, Betz-Stablein, B.2, Martin, P.L.1,
Szabolcs, P.1, Prasad, V.K.1, Driscoll, T.A.1, Kurtzberg, J.1 1Duke
University Medical Center, Durham, NC; 2Emmes Corporation,
Rockville, MD
Myelodysplastic syndromes (MDS) respond poorly to chemother-
apy alone. Between 1995 and 2006, 23 pediatric patients with MDS
were transplanted with unrelated donor umbilical cord blood
(UCB) at our center. The median age was 11.09 yrs (range 1.11–
19.73); 20% of patients were male; median time from diagnosis to
transplant was 6.57 mo (range 2.00–61.37). Patients were followed
for amedianof 5.3 yrs (range1.64–12.36) post-transplant.MDSstage
wasRA/RC12pts,RAEB8pts andRAEB-T3pts; 78.3%pts hadpri-
maryMDS.Monosomy7waspresent in 17(74%)of patients. Patients
with frank AML were excluded. Preparative regimen was TBI based
in 18 (78%) pts and melphalan was used in 14 (61%) of patients.
GVHD prophylaxis consisted of CSA/steroids (19 pts) and CSA/
MMF (4 pts). Grafts were HLA matched at Class I (A and B) at low
resolution and Class II (DRB1) at the allelic level resulting in
16(70%) 4/6 and 7(30%) 5/6 matched transplants. The grafts con-
tained amedian of 4.04 107 (range 1.68–12.58) total nucleated cells
(TNC)/kg pre-cryopreservation; 3.58  107 (range 1.01–12.00)
TNC/kg and1.72 105 (range 0.17–28.46)CD341 cells/kgwere in-
fused. Cumulative incidence of neutrophil engraftment (ANC.500/
mL) at days 42 & 100 was 73.9% (95%CI 55.1%–92.7%) and 91.3%
(95%CI71.3%–100%), and that of platelet engraftment (50K) at 180
days was 69.6% (49.8%–89.4%). Three pts had graft failure while 3
pts (13%) engrafted slowly (after Day 42), perhaps related to some
underlying marrow dysfunction caused by MDS. Three patients de-
veloped acuteGvHDgrades II-IVwith a cumulative incidence at 100
Days of 13% (95% CI 0.0%–27.1.0%). Four patients relapsed with
a CI of relapse at 3 yrs of 13.0% (95%CI 0.0%–27.1%). Cumulative
incidence of non-relapse mortality at 1 yr was 27% (95% CI 8.0%–
46.0%). Ten pts died: 3 graft failure, 4 relapse, 2 infections (1 adeno-
virus, 1 toxoplasmosis), and 1 EBVLPD.Overall survival probability
at 1 and3 yearswere 69.6%(95%CI46.6%–84.2%) and59.2% (95%
CI 35.9%–76.5%) respectively. Event-free survival (EFS) probabili-
ties at 1 and 3 years were 69.6% (95% CI 46.6%–84.2%) and 60.9%
(38.3%–77.4%) respectively. Factors associated with better EFS
were age # 10 yrs (p 5 0.05) and weight # 38 kg (p 5 0.03). These
results, especially in younger pts with Monosomy 7 and MDS, are
equivalent to published matched allogeneic bone marrow data.
UCB should be actively considered for pediatric MDS pts lacking
matched related or unrelated adult donors.197
A PHASE I/II STUDY OF CYCLOPHOSPHAMIDE AND TOPOTECAN IN PA-
TIENTS WITH HIGH-RISK MALIGNANCIES UNDERGOING AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE ST. JUDE LONG-
TERM FOLLOW-UP
Kasow, K.A.1, Barfield, R.C.2, Wright, N.L.1, Li, C.1, Srivastava, D.K.1,
Horwitz, E.M.3, Leung, W.1, Woodard, P.1, Bowman, L.C.1,
Handgretinger, R.4, Hale, G.A.1 1St, Jude Children’s Research Hospital,
Memphis, TN; 2Duke University, Durham, NC; 3Children’s Hospital of
Philadelphia, Philadelphia, PA; 4University of Tuebingen, Tuebingen,
Germany
Poster Session-I 7358 consecutive children with high-risk lymphomas and solid tu-
mor malignancies were treated with cyclophosphamide and tar-
geted topotecan followed by autologous HSCT as consolidation
therapy in a phase I/II IRB-approved study between November
1998 and January 2004 at St. Jude. 21 participants (pts) were en-
rolled in the phase I portion of the study. 14 pts were enrolled in
phase I, level 1 consisting of topotecan 3mg/m2/day with subse-
quent doses targeted to total systemic exposure of 100 6 20 ng-
hr/ml (days -11 to -2) and cyclophosphamide 750mg/m2/day on
days -6 through -2 (total, 3.75g/m2). Topotecan concentrations
were measured on days -11 and -6 to determine subsequent dosage
adjustments. Cyclophosphamide dose escalation to 1g/m2/day (to-
tal, 5g/m2) on level 2 was excessively toxic, as 7 of 7 pts experienced
$ grade 3 regimen-related toxicity; 1 pt died of veno-occlusive dis-
ease. The next 37 pts were enrolled in phase II at level 1 as maxi-
mum tolerated dose was reached; further results will be on the 51
pts who received cyclophosphamide and topotecan at dose level 1.
Pts included neuroblastoma (26), sarcoma (8), lymphoma (8), brain
tumor (5), Wilms tumor (3), and retinoblastoma (1). Disease status
at enrollment included 11 (21.6%) CR1, 10 (19.7%) $CR2, 9
(17.6%) very good partial response, 7 (13.7%) partial response, 2
(3.9%) progressive disease, 10 (19.6%) stable disease, and 2
(3.9%) relapse disease. Median age at HSCT was 4.9 years (y)
(range, 1.5–21.3 y) and 52.9% were males. Of the 51 pts, 19 re-
ceived unmanipulated peripheral blood stem cell grafts and 32 mar-
row grafts. Most common grade 3 or 4 toxicities were hepatic,
gastrointestinal and skin. Pts achieved neutrophil and platelet en-
graftment at a median of 13 days (range, 8–33 days) and 24 days
(range, 8–91 days), respectively. Overall the median time to neutro-
phil engraftment for pts receiving marrow grafts was 18 days
(range, 10–33 days) and PBSC grafts 10 days (range, 8–12 days)
(p\ 0.0001). 25 (49%) remain alive at a median of 6.4 y (range,
4–9.8 y). 3- and 5-year OS and EFS for all and most common di-
agnoses are described in Table 1; none were statistically significant.
Cyclophosphamide 3.75g/m2 and targeted topotecan followed by
autologous HSCT produces acceptable toxicity and ability to
achieve long-term survival in children with high-risk lymphoma
and solid tumor malignancies; hepatic toxicity was dose-limiting
in the initial phase of the study.
The 3-year and 5-year OS and EFS for the 3 most common
diagnoses and all participants treated on this therapeutic
protocol.
3-year OS 3-year EFS 5-year OS 5-year EFSNeuroblastoma 73.1% 1/- 8.5% 42.3% 1/- 9.3% 57.7% 1/- 10.8% 38.5% 1/- 11.4%Lymphoma 75% 1/- 14.2% 50% 1/- 15.8% 75% 1/- 14.2% 50% 1/- 15.8%Sarcoma 50% 1/- 15.8% 37.5% 1/- 14.8% 50% 1/- 17.7% 37.5% 1/- 17.1%Total 64.7% 1/- 6.6% 41.2% 1/- 6.7% 56.7% 1/- 7.8% 39.2% 1/- 8.2%OS, overall survival; EFS, event-free survival198
PHOTO(CHEMO)THERAPY IN THE TREATMENT OF CUTANEOUS
CHRONIC GRAFT VERSUS HOST DISEASE IN CHILDREN AND ADOLES-
CENTS
Lawitschka, A.1, Tanew, A.2, Seidel, M.1, Guclu, E.1, Peters, C.1
1St. Anna Childrens Hospital, Vienna, Austria; 2Medical University,
Vienna, Austria
Steroid and immunosuppressant sparing treatments of cutaneous
chronic graft versus host disease (GVHD) in children are a desirable
strategy, due to serious side-effects especially on growing and devel-
oping children. Photo(chemo)therapy (PT) has been shown to exert
local immunomodulatory activity in a variety of diseases including
GVHD. Therefore, we investigated the effect of total 31 cycles of
PT (narrowband UVB, UVA-1, PUVA) in 28 pediatric patients
(pat.)with cutaneous cGVHD (10 lichenoid, 18 sclerodermoid). 25/
28 pat. (89%) presented with extensive GVHD and have been either
resistant to immunosuppressive therapy or showed contraindications
against standard immunosuppression. Underlying diseases for allo-
geneic stem cell transplantation were malignant and non malignant
diseases (18 and10, respectively) with a median follow up of 8,7 years(2.7–17.7). Stem cell source were bone marrow in 20/28 and periph-
eral blood in 8/28 pat. given aftermyeloablativ conditioning in 18 and
after reduced intensity conditioning in 10 pat. Topical therapy in all
pat. comprised corticosteroids and, in recent years pimecrolimus.
Treatment outcome after 10 UVA-1, 8 narrowband UVB, 7 oral
PUVA and 6 topical PUVA courses was evaluated retrospectively.1
pat. got narrowband-UVB monotherapy, 5 pat. received one and
21 pat. two and more systemic immunosuppressants in addition to
PT. PT was well tolerated by all pat. Improvement of skin lesions
was observed in all but one (96%) pat. Complete remission (CR)
was achieved in 7/31 (22%)courses, a very good partial response
(VGPR) that allowed tapering of immunosuppressive therapy and re-
sulted inCR in another 8 (25%). 8 courses (25%) induced a partial re-
sponse (PR) with subsequent tapering of immunosuppressants and
stable disease, 3 courses (9,6%) also led to PR but were followed by
relapse. 1 course was without effect (NR). One pat. did not respond
initially to narrowband UVB but completely cleared after being
switched to UVA-1 treatment.We conclude that PT is a feasible,
nonaggressive treatment that may be beneficial for pediatric patients
with cutaneousGVHDby reducingprolonged systemic immunosup-
pressive therapy. Further controlled prospective studies are required
to prove our expectations especially inUVA-1 as addon treatment for
sclerodermoid, extensive cutaneous GVHD in children.199
PERICARDIAL EFFUSION FOLLOWING UNRELATED UMBILICAL CORD
BLOOD TRANSPLANTATION: ANALYSIS IN A COHORT OF 423 PEDIATRIC
PATIENTS TRANSPLANTED AT A SINGLE CENTER
Hwang, E.I.1, Camitta, M.G.W.2, Vinesett, R.3, Mendizabal, A.4,
Wood, S.3, Semmel, D.3, Page, K.3, Driscoll, T.A.3, Parikh, S.H.3,
Szabolcs, P.3, Martin, P.L.3, Kurtzberg, J.3, Prasad, V.K.3 1Duke
University Medical Center, Durham, NC; 2Duke University Medical
Center, Durham, NC; 3Duke University Medical Center, Durham,
NC; 4The EMMES Corporation, Rockville, MD
Background: Pericardial effusion (PCE) has only sporadically
been reported in transplant recipients. We studied a large series of
pediatric patients undergoing unrelated umbilical cord blood trans-
plantation (UCBT) at a single center to investigate PCE comprehen-
sively.
Methods: Between 01/2000 and 05/2008, 423 consecutive pa-
tients (median age 4.3 years; range 0.1–20.2 years) undergoing
UCBT from a single cord blood unit (CBU) after myeloablative con-
ditioning regimen were studied (median follow-up 1.8 years; range,
0.5–8.7 years). By low resolutionHLA-A and –B and high resolution
–DRB1 matching the CBU were 4/6 (53.8%), 5/6 (35.3%), or 6/6
(8.5%) matched. The patients (63% male; 33% CMV seropositive)
hadmalignant (53.2%; n5 225; leukemia, lymphoma,MDS, others)
and non-malignant (46.8%; n5 198; metabolic, immunodeficiency,
marrow failure; and hemoglobinopathies) diagnoses. Cytoreduction
contained TBI for 38.3% and cyclophosphamide for 69.5%
patients. The graft-vs.-host disease (GVHD) prophylaxis was
cyclosporine1cellcept in 25.8% (n 5 109) and cyclospori-
ne1methylprednisone in 73% (n 5 309) patients.
Results: A total of 108 (26%) patients developed at least one ep-
isode of PCE a median of 96 days (range, 9 – 2730 days) after trans-
plant. PCE severity was moderate to very large in 56 and very small
to moderate in 52 patients. Cardiac tamponade was seen in 28
(6.7%); pericardiocentesis was performed in 31 (7.3%); and 10
(2.4%) patients required pericardial window. Pericardial fluid did
not reveal infection by cytology, cultures, PCR, or other tests. Cu-
mulative incidence of PCE in patients with grades II-IV acute
GVHD was 35% compared to 22% in those with either grade I or
no evidence of acute GVHD. TBI, patient CMV serostatus, HLA
match, chronic GVHD, age or sex of the patient had no impact on
the incidence of PCE. PCE with tamponade was significantly higher
(p 5 0.02) and pericardiocentesis was needed more often (p 5 0.03)
in the patients on cellcept prophylaxis. The 1-yr post-UCBT
survival in patients developing PCE was 55% compared to 63% in
those without PCE. Twenty-eight (6.7%) patients with PCE had
concomitant pleural and/or peritoneal fluid collection consistent
with a ‘‘polyserositis syndrome’’.
Conclusion: Pericardial effusion occurs in a quarter of UCBT
recipients but only a few are clinically important. Large PCE
